secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001093557-24-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B
--------------------------------------------------------------------------------

- Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.
- Non-GAAP operating margin 15.2% (up 460 bps YoY); Non-GAAP EPS $0.32.
- FDA cleared Stelo, first OTC CGM for type 2 diabetes not on insulin; also cleared Direct-to-Watch for G7.
- Updated FY2024 revenue guidance to $4.20-4.35B (17-21% organic growth); reiterated Non-GAAP gross margin ~63-64% and operating margin ~20%.
- Cash $2.9B; revolving credit facility undrawn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/0001093557-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355724000078/dxcm-20240425.htm
  HTML page:      https://secwatch.observer/filing/0001093557-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer